Key Findings
- 2002 Suboxone was approved by the FDA to treat recovering opioid addicts.
- 2010 The FDA approved a sublingual version of Suboxone.
- 2002-2022, 171 million prescriptions were dispensed in the US.
- 2019 Suboxone was top 10 Medicaid prescription dispensed by spend.
- 2021 FDA Issued a Safety Communication warning of dental problems associated with buprenorphine dissolved by mouth.
- 2022 The FDA required a warning label update after hundreds of reports of dental decay and permanent damage of teeth to Suboxone users.
Research Studies
- Case study conducted at Brigham and Women’s Hospital in 2012, “Sublingual Buprenorphine and Dental PRoblems: A Case Series” found an association with worsening dental health after initiation of buprenorphine.
- Research letter published in JAMA in December 2022, “Association Between Sublingual Buprenorphine-Naloxone Exposure and Dental Disease” indicated a doubling in the risk of severe dental decay.
Current Criteria
- Prescribed Suboxone prior to July 2022.
- No documented illicit drug use.
- Documented tooth decay complications:
- Severe tooth decay
- Tooth loss
- Broken teeth
- Tooth extractions
- Jaw bone deterioration
- Underwent oral surgery
- Required dental implants
Estimated Case Values
Range: $50,000 – $150,000. Average Value: $75,000.
Current Status of Litigation
Miller & Zois has an updated current status of the litigation.
Pricing
Option 1: Pricing: 700-900 per intake (based on criteria)
Option 2: If your firm previously targeted individuals for the opioid cases, we can reach out to these potential claimants on your behalf for $250 per intake. If the conversions are 15% or better, we can charge $200 per intake.
Please contact me at david@stanfordwharton.com or +1.786.303.2843 for more details.
